Randomized Clinical Trial for Clinical Response Evaluation in Crohn's Disease: Infliximab Versus Adalimumab

dc.contributorFac Med Botucatu
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2018-11-28T03:51:17Z
dc.date.available2018-11-28T03:51:17Z
dc.date.created2018-11-28T03:51:17Z
dc.date.issued2016-03-01
dc.identifierInflammatory Bowel Diseases. Philadelphia: Lippincott Williams & Wilkins, v. 22, p. S30-S30, 2016.
dc.identifier1078-0998
dc.identifierhttp://hdl.handle.net/11449/165476
dc.identifier10.1097/01.MIB.0000480181.61935.67
dc.identifierWOS:000393896400092
dc.languageeng
dc.publisherLippincott Williams & Wilkins
dc.relationInflammatory Bowel Diseases
dc.relation2,511
dc.rightsAcesso restrito
dc.sourceWeb of Science
dc.titleRandomized Clinical Trial for Clinical Response Evaluation in Crohn's Disease: Infliximab Versus Adalimumab
dc.typeOtros


Este ítem pertenece a la siguiente institución